Association of the Immature Platelet Fraction with Sepsis Diagnosis and Severity

Overview

Journal Sci Rep

Specialty Science

Date 2015 Jan 27

PMID 25620275

Citations 19

Authors

Rodolfo Monteiro Enz Hubert

Melina Veiga Rodrigues

Bruna Dolci Andreguetto

Thiago M Santos

Maria de Fatima Pereira Gilberti

Vagner de Castro

Joyce M Annichino-Bizzacchi

Desanka Dragosavac

Marco Antonio Carvalho-Filho

Erich Vinicius De Paula

Affiliations

Soon will be listed here.

Abstract

Management of Sepsis would greatly benefit from the incorporation of simple and informative new biomarkers in clinical practice. Ideally, a sepsis biomarker should segregate infected from non-infected patients, provide information about prognosis and organ-specific damage, and be accessible to most healthcare services. The immature platelet fraction (IPF) and immature reticulocyte fraction (IRF) are new analytical parameters of the complete blood count, that have been studied as biomarkers of several inflammatory conditions. Recently, a study performed in critically-ill patients suggested that IPF could be a more accurate sepsis biomarker than C-reactive protein (CRP) and procalcitonin. In this retrospective study we evaluated the performance of IPF and IRF as biomarkers of sepsis diagnosis and severity. 41 patients admitted to two intensive care units were evaluated, 12 of which with severe sepsis or septic shock, and 11 with non-complicated sepsis. Significantly higher IPF levels were observed in patients with severe sepsis/septic shock. IPF correlated with sepsis severity scores and presented the highest diagnostic accuracy for the presence of sepsis of all studied clinical and laboratory parameters. No significant differences were observed in IRF levels. Our results suggest that IPF levels could be used as a biomarker of sepsis diagnosis and severity.

Citing Articles

Thrombocytopenia in Sepsis.

Setarehaseman A, Mohammadi A, Maitta R Life (Basel). 2025; 15(2).

PMID: 40003683 PMC: 11857489. DOI: 10.3390/life15020274.

Immature Platelets and Platelet Reactivity in Patients with COVID-19.

Balmakov Y, Mark T, Barnett I, Cipok M, Lev E, Cohen A Clin Appl Thromb Hemost. 2025; 31:10760296251318320.

PMID: 39943824 PMC: 11826839. DOI: 10.1177/10760296251318320.

Deciphering Abnormal Platelet Subpopulations in COVID-19, Sepsis and Systemic Lupus Erythematosus through Machine Learning and Single-Cell Transcriptomics.

Qiu X, Nair M, Jaroszewski L, Godzik A Int J Mol Sci. 2024; 25(11).

PMID: 38892129 PMC: 11173046. DOI: 10.3390/ijms25115941.

Sepsis-Induced Coagulopathy: An Update on Pathophysiology, Biomarkers, and Current Guidelines.

Tsantes A, Parastatidou S, Tsantes E, Bonova E, Tsante K, Mantzios P Life (Basel). 2023; 13(2).

PMID: 36836706 PMC: 9961497. DOI: 10.3390/life13020350.

Changes in Platelet Function in Preterm Newborns with Prematurity Related Morbidities.

Franciuc I, Matei E, Aschie M, Mitroi A, Chisoi A, Poinareanu I Children (Basel). 2022; 9(6).

PMID: 35740728 PMC: 9221979. DOI: 10.3390/children9060791.

References

Alves B, Montalvao S, Aranha F, Lorand-Metze I, De Souza C, Annichino-Bizzacchi J . Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study. J Transl Med. 2011; 9:23. PMC: 3058017. DOI: 10.1186/1479-5876-9-23. View

Fiotti N, Mearelli F, Ruscio M, Altamura N, Vinci P, Fernandes G . Procalcitonin in early rule-in/rule-out of sepsis in SIRS patients admitted to a medical ward. Clin Chem Lab Med. 2014; 52(10):1473-8. DOI: 10.1515/cclm-2014-0196. View

Caudrillier A, Kessenbrock K, Gilliss B, Nguyen J, Marques M, Monestier M . Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012; 122(7):2661-71. PMC: 3386815. DOI: 10.1172/JCI61303. View

McDonald B, Urrutia R, Yipp B, Jenne C, Kubes P . Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe. 2012; 12(3):324-33. DOI: 10.1016/j.chom.2012.06.011. View

Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S . Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41(2):580-637. DOI: 10.1097/CCM.0b013e31827e83af. View

De Blasi R, Cardelli P, Costante A, Sandri M, Mercieri M, Arcioni R . Immature platelet fraction in predicting sepsis in critically ill patients. Intensive Care Med. 2012; 39(4):636-43. DOI: 10.1007/s00134-012-2725-7. View

Gaieski D, Edwards J, Kallan M, Carr B . Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013; 41(5):1167-74. DOI: 10.1097/CCM.0b013e31827c09f8. View

Clerico A, Plebani M . Biomarkers for sepsis: an unfinished journey. Clin Chem Lab Med. 2013; 51(6):1135-8. DOI: 10.1515/cclm-2013-0003. View

Di Somma S, Magrini L, Travaglino F, Lalle I, Fiotti N, Cervellin G . Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department. Clin Chem Lab Med. 2013; 51(6):1167-75. DOI: 10.1515/cclm-2012-0795. View

10.

Meintker L, Haimerl M, Ringwald J, Krause S . Measurement of immature platelets with Abbott CD-Sapphire and Sysmex XE-5000 in haematology and oncology patients. Clin Chem Lab Med. 2013; 51(11):2125-31. DOI: 10.1515/cclm-2013-0252. View

11.

Lee E, Kim S, Song Y, Choi S, Song J . Immature platelet fraction in diabetes mellitus and metabolic syndrome. Thromb Res. 2013; 132(6):692-5. DOI: 10.1016/j.thromres.2013.09.035. View

12.

Larsen S, Grove E, Hvas A, Kristensen S . Platelet turnover in stable coronary artery disease - influence of thrombopoietin and low-grade inflammation. PLoS One. 2014; 9(1):e85566. PMC: 3897460. DOI: 10.1371/journal.pone.0085566. View

13.

Wiersinga W, Leopold S, Cranendonk D, van der Poll T . Host innate immune responses to sepsis. Virulence. 2013; 5(1):36-44. PMC: 3916381. DOI: 10.4161/viru.25436. View

14.

Morrell C, Aggrey A, Chapman L, Modjeski K . Emerging roles for platelets as immune and inflammatory cells. Blood. 2014; 123(18):2759-67. PMC: 4007605. DOI: 10.1182/blood-2013-11-462432. View

15.

Opal S, Dellinger R, Vincent J, Masur H, Angus D . The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med. 2014; 42(7):1714-21. PMC: 4135726. DOI: 10.1097/CCM.0000000000000325. View

16.

Lesko L, Atkinson Jr A . Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001; 41:347-66. DOI: 10.1146/annurev.pharmtox.41.1.347. View

17.

Sackett D, Haynes R . The architecture of diagnostic research. BMJ. 2002; 324(7336):539-41. PMC: 1122451. DOI: 10.1136/bmj.324.7336.539. View

18.

Frank R, Hargreaves R . Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003; 2(7):566-80. DOI: 10.1038/nrd1130. View

19.

Briggs C, Kunka S, Hart D, Oguni S, Machin S . Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004; 126(1):93-9. DOI: 10.1111/j.1365-2141.2004.04987.x. View

20.

Knaus W, Draper E, Wagner D, Zimmerman J . APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10):818-29. View